Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods [Clinical Trials]
Conclusion
The absolute and relative change metrics are not meaningfully better than RECIST in predicting OS.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: An, Han, Meyers, Bogaerts, Sargent, Mandrekar Tags: Clinical Trials Source Type: research